{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:38:08Z","timestamp":1793911088597,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.rmed.2026.109151","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:52:28Z","timestamp":1789141948000},"page":"109151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Activin pathway inhibition and rapid progression of malignancy in pulmonary arterial hypertension: A case series and hypothesis"],"prefix":"10.1016","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2321-9545","authenticated-orcid":false,"given":"Adriano R.","family":"Tonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulwant S.","family":"Aulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Berro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin B.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.109151_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"* PI. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.rmed.2026.109151_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251342898","article-title":"Treatment of pulmonary hypertension after seven world symposia","volume":"19","author":"Estrada","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.rmed.2026.109151_bib3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2024.107442","article-title":"Sotatercept: new drug on the horizon of pulmonary hypertension","volume":"157","author":"Madonna","year":"2024","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.rmed.2026.109151_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib6","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1210\/en.2006-0444","article-title":"Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a Smad-independent manner","volume":"147","author":"de Guise","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.rmed.2026.109151_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2017.01.011","article-title":"Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling","volume":"391","author":"Dean","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.rmed.2026.109151_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","article-title":"Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth","volume":"332","author":"Tamminen","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.rmed.2026.109151_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cytogfr.2006.01.001","article-title":"Roles of activin in tissue repair, fibrosis, and inflammatory disease","volume":"17","author":"Werner","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.rmed.2026.109151_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021881","article-title":"Activins and inhibins: roles in development, physiology, and disease","volume":"8","author":"Namwanje","year":"2016","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.rmed.2026.109151_bib11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14728222.2020.1799350","article-title":"Activin A: an emerging target for improving cancer treatment?","volume":"24","author":"Ries","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.rmed.2026.109151_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116061","article-title":"Activin receptors in human cancer: functions, mechanisms, and potential clinical applications","volume":"222","author":"Du","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.rmed.2026.109151_bib13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/bjc.2011.348","article-title":"Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer","volume":"105","author":"Kaneda","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.rmed.2026.109151_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/cancers7010070","article-title":"Intertwining of activin A and TGFbeta signaling: dual roles in cancer progression and cancer cell invasion","volume":"7","author":"Loomans","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmed.2026.109151_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102314","article-title":"Activin-A in the regulation of immunity in health and disease","volume":"104","author":"Morianos","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.rmed.2026.109151_bib16","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1038\/s41598-025-91853-9","article-title":"Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner","volume":"15","author":"Wiley","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2026.109151_bib17","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/0008-5472.CAN-15-2668","article-title":"BAFF and APRIL from activin A-Treated dendritic cells upregulate the antitumor efficacy of dendritic cells in vivo","volume":"76","author":"Shurin","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.rmed.2026.109151_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12000","article-title":"Pulmonary hypertension is associated with an increased incidence of cancer diagnoses","volume":"12","author":"Roderburg","year":"2022","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.rmed.2026.109151_bib19","article-title":"Unmasking cancer risk in heritable PAH: the hidden role of BMPR2 in epithelial tumorigenesis","volume":"30","author":"Biscotti","year":"2025","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.rmed.2026.109151_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/CLEP.S345054","article-title":"Cancer risk in pulmonary hypertension patients","volume":"14","author":"Sorensen","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2026.109151_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.rdc.2020.03.002","article-title":"Cancer and scleroderma","volume":"46","author":"Weeding","year":"2020","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.rmed.2026.109151_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molonc.2014.08.004","article-title":"BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation","volume":"9","author":"Pickup","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.rmed.2026.109151_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/j.gastro.2023.03.006","article-title":"BMPR2 as a novel predisposition gene for hereditary colorectal polyposis","volume":"165","author":"Bonjoch","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rmed.2026.109151_bib24","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8318","article-title":"Activin A promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer","volume":"47","author":"Daitoku","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.rmed.2026.109151_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cellsig.2003.11.002","article-title":"Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1","volume":"16","author":"Ho","year":"2004","journal-title":"Cell. Signal."},{"key":"10.1016\/j.rmed.2026.109151_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jsgi.2003.10.008","article-title":"High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer","volume":"11","author":"Cobellis","year":"2004","journal-title":"J. Soc. Gynecol. Invest."},{"key":"10.1016\/j.rmed.2026.109151_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1541-7786.50.3.1","article-title":"Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells","volume":"3","author":"Steller","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.rmed.2026.109151_bib28","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.rmed.2026.109151_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01435-2024","article-title":"A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA","volume":"66","author":"Preston","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.109151_bib30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.rmed.2026.109151_bib33","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1016\/S2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Della Porta","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.rmed.2026.109151_bib34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","article-title":"Development of luspatercept to treat ineffective erythropoiesis","volume":"5","author":"Kubasch","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.rmed.2026.109151_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109151_bib38","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2352-3026(24)00376-4","article-title":"Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent beta-thalassaemia (BELIEVE): final results from a phase 3 randomised trial","volume":"12","author":"Cappellini","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.rmed.2026.109151_bib39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01435-2024","article-title":"A long-term Follow-Up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA","author":"Preston","year":"2025","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:16:02Z","timestamp":1793909762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126005202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S0954611126005202"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109151","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activin pathway inhibition and rapid progression of malignancy in pulmonary arterial hypertension: A case series and hypothesis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109151"}}